Analystreport

Jounce Therapeutics Inc (NASDAQ: JNCE) is now covered by analysts at Roth Capital. They set a "buy" rating and a $28.00 price target on the stock.

Jounce Therapeutics, Inc.  (JNCE) 
Last jounce therapeutics, inc. earnings: 2/27 06:30 am Check Earnings Report
US:NASDAQ Investor Relations: ir.jouncetx.com